Grifols-Talecris Deal Makes Arbitragers See 60% Gain

Grifols-Talecris Deal Makes Arbitragers See 60% Gain

Grifols S.A. via Bloomberg

Investors have grown more bullish on Talecris since Grifols, Europe’s largest maker of blood-plasma products, extended the acquisition’s closing last month as it seeks antitrust approval.